UK Biotech given green light to begin stem cell therapy clinical trial for heart failure

UK biotech, Celixir, has received a green light to start a phase IIb trial of HeartCel, its stem cell-based therapy for heart failure, that could potentially support approval. Heartcel is a preparation of off-the-shelf immunomodulatory progenitor (iMP) cells that are injected around cardiac scar tissue during coronary artery bypass graft (CABG) surgery in the hope

Continue Reading

Recent study data by the FDA has found that older blood cancer patients (75+) are severely under-represented in clinical trials

Results from the FDA’s first comprehensive examination of clinical trial enrolment in older patients with blood cancers has revealed that patients over 75 are significantly underrepresented. When looking at the occurrence of these conditions, it has recently been found that one in five patients in the US who are diagnosed with blood cancer are over

Continue Reading

CCRA AGM Roundup 2017

Housed within the dramatic and suitably clinical-feeling Miller Insurance offices near Aldgate in London, a gathering of great clinical minds occurred for the CCRA AGM. Professor Atholl Johnston, President, opened up the day with introductions before we launched into 5 presentations back-to-back. Firstly we heard from Andy Catton, a Partner at Miller Insurance, on specialist

Continue Reading

Ipsen and Exelixis’s treatment for liver cancer, Cabometyx, sees positive Phase III trial results

Ipsen’s collaboration with Exelixis is on track to file cancer treatment, Cabometyx, for a new liver cancer indication in the first half of next year, following positive Phase III trial results. The randomised, double-blind CELESTIAL study was set up to test Cabometyx in 760 patients who have advanced hepatocellular carcinoma (HCC), which is the sixth

Continue Reading

Bloodwise funded clinical trial identifies genetic fault in leukaemia patients that affects response to treatment

A recently conducted clinical trial has found a genetic fault that has been identified in people with an aggressive type of leukaemia that notably affects how the patient responds to treatment. Findings from a clinical trial conducted by University of Birmingham examined whether survival times for those with acute myeloid leukaemia (AML) or myelodysplastic syndrome

Continue Reading

New Academy Programme Launches!

Did you know over 70% of the clinical research sector lack operational training around ICH/GCP changes, based on a recent survey. The Clinical Professionals’ Academy team are proud to announce the development of yet another unique training course that has been invested in by us to answer the needs of industry. This programme looks to

Continue Reading

The Future of Clinical Trials

By Doug Stewart –Director of Hosted Employment and The Training Academy In 2015, Professor Allen Frances of Duke University published an article sharing his fears, concerns and indeed, open scorn for the current methodologies of pharmaceutical clinical trials. “It’s been many years since I have trusted anything I read in a medical or psychiatric journal.

Continue Reading